$KNSA News

Kiniksa Pharmaceuticals to Present at Wells Fargo 21st Annual Healthcare Conference

Kiniksa Pharmaceuticals (NASDAQ:KNSA) Combines High Growth Momentum with a Breakout Setup

Kiniksa Pharmaceuticals (NASDAQ:KNSA) Shows Strong Growth and a Technical Setup for a Potential Breakout

Kiniksa's Sales Are Expected To Decline — Why That's All According To Plan

Kiniksa Pharmaceuticals (NASDAQ:KNSA): A Compelling Affordable Growth Story

Kiniksa Highlights ARCALYST Growth as KPL-387 Advances Into Phase 3

Kiniksa Pharmaceuticals to Present at Canaccord Genuity 46th Annual Growth Conference

KNSA Q2 Earnings Call Backs Higher ARCALYST Sales Outlook

Kiniksa Pharmaceuticals International, plc 2026 Q2 - Results - Earnings Call Presentation

Earnings Estimates Rising for Kiniksa Pharmaceuticals International, plc (KNSA): Will It Gain?

Goldman Sachs Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $90

Could Kiniksa Pharmaceuticals International (KNSA) Be 16% Overvalued After Raised 2026 Guidance?

Why Kiniksa Pharmaceuticals (KNSA) Is Up 29.6% After Raising 2026 Revenue Guidance And Advancing Pipeline

JP Morgan Maintains Overweight on Kiniksa Pharmaceuticals, Raises Price Target to $107

Canaccord Genuity Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $98

Wedbush Maintains Outperform on Kiniksa Pharmaceuticals, Raises Price Target to $99

Citigroup Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $100

Kiniksa Reports Strong Q2 Results, Raises 2026 ARCALYST Sales Guidance

Kiniksa Pharmaceuticals International Q2 Earnings Call Highlights

Kiniksa Pharmaceuticals International, plc (KNSA) Q2 Earnings Match Estimates